Full-Time

Platform Engineer

Automation

Posted on 2/27/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Zaragoza, Spain + 1 more

More locations: Pune, Maharashtra, India

In Person

Category
DevOps & Infrastructure (1)
Required Skills
PowerShell
Microsoft Azure
Python
SQL
AWS
DevOps
Linux/Unix
Google Cloud Platform
Requirements
  • Experience with cloud platforms (e.g., AWS, Azure, GCP).
  • Knowledge of operating systems (e.g., Windows, Linux)
  • Scripting skills (e.g., PowerShell, Python).
  • Basic knowledge of SQL databases.
  • Experience with DevOps practices (CI/CD, configuration management, collaboration tools).
  • Design, implement, and maintain the infrastructure for automation platforms (RPA, BPM) in alignment with central teams.
  • Cloud infrastructure knowledge (e.g., virtual machines, databases, network, and other resources) to choose the right infrastructure/needs.
  • 2+ years of experience in software development or platform engineering.
  • 2+ years proven experience in a technical cloud engineering role
  • Strong proficiency in relevant programming languages and technologies.
Responsibilities
  • Assist in the design and development of PLATFORM solutions, ensuring scalability and performance.
  • Provide technical PLATFORM guidance and support to the development team, especially in the context of BPM/RPA applications.
  • Help manage project timelines and deliverables, ensuring technical tasks align with defined business goals.
  • Support PLATFORM infrastructure enhancements to improve robustness and support RPA deployments.
  • Conduct in-depth market research to identify industry trends and innovations that could enhance platform capabilities
  • Contribute to efforts to optimize platform performance and reliability through continuous assessment and tuning of RPA systems.
  • Explore and integrate new technologies to foster innovation and expand platform capabilities, particularly in RPA.
  • Assist in developing and implementing scalable solutions to address evolving business needs in automation.
  • Regularly monitor and analyze platform performance metrics, to identify and implement improvements.
  • Engage in proactive planning to ensure readiness in platform provisioning, preventing deployment hindrances.
  • Support release management strategies to ensure timely and efficient deployment of platform updates.
  • Assist in designing and configuring testing environments to support platform deployment, ensuring alignment with operational requirements.
  • Conduct assessments to ensure platforms comply with security standards and regulatory requirements, focusing on security.
  • Implement measures to enhance platform security and reduce vulnerabilities.
  • Collaborate with automation team members, Infrastructure, IT Security, and other stakeholders to align platform strategies with business objectives.
  • Ensure technical solutions are consistent with enterprise architecture standards.
  • Effectively communicate analytical findings and recommendations to technical and executive audiences.
  • Conduct in-depth market research to identify industry trends and innovations that could enhance platform capabilities, particularly in RPA and BPM.
  • Stay informed about future BPM technologies that could be integrated into Cencora, such as process mining, intelligent process automation, and workflow automation tools.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty pharmaceuticals remain the main growth engine for higher-margin services.
  • Management targets $300 million in savings while sustaining about $3 billion free cash flow.
  • Share repurchases and accretive acquisitions can support earnings per share.

What critics are saying

  • Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
  • Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
  • Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.

What makes Cencora unique

  • Cencora combines drug distribution, specialty pharmacy, and patient-support services.
  • It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
  • The company is expanding specialty care through OneOncology and EyeSouth retina assets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE